PMV Pharmaceuticals
PMVP
92 hedge funds and large institutions have $1.31B invested in PMV Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 34 increasing their positions, 27 reducing their positions, and 7 closing their positions.
86% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 7
26% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 27
7% more funds holding
Funds holding: 86 → 92 (+6)
3.29% more ownership
Funds ownership: 93.84% → 97.13% (+3.3%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
9% less capital invested
Capital invested by funds: $1.44B → $1.31B (-$132M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$38.1M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$35.1M |
| 3 |
State Street
Boston,
Massachusetts
|
+$26.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.1M |
| 5 |
RI
RTW Investments
New York
|
+$10.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
Euclidean Capital
New York
|
-$36.4M |
| 2 |
IVM
InterWest Venture Management
San Francisco,
California
|
-$35.1M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$33.1M |
| 4 |
PA
Perceptive Advisors
New York
|
-$14.2M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$7.5M |
PMVP Hedge Fund Activity: Q3 2021 in Review
92 of the 5,729 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q3 2021, worth a combined $1.31B — down 9.2% from $1.44B a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new PMVP positions and 7 closed out — a net gain of 6 holders — while 34 added to existing stakes and 27 trimmed.
The largest buyer was Logos Global Management, adding an estimated $38.1M. The largest seller was Euclidean Capital, cutting an estimated $36.4M.
- 92 institutional investors held PMV Pharmaceuticals (PMVP) as of Q3 2021, up from 86 in Q2 2021.
- Funds reported $1.31B of PMV Pharmaceuticals stock for Q3 2021, down 9.2% quarter-over-quarter.
- 13 funds opened new PMV Pharmaceuticals positions in Q3 2021 and 7 closed out, a net change of +6 holders.
- The largest PMV Pharmaceuticals buyer in Q3 2021 was Logos Global Management, an estimated $38.1M added.
- The largest PMV Pharmaceuticals seller in Q3 2021 was Euclidean Capital, an estimated $36.4M sold.
Based on aggregated 13F filings for Q3 2021.